ABBV Fair Value Estimate
$131.6836.9% overvalued
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Abbvie Inc
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio.
Did you know?
Generated $14.7 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
$208.84
-2.86%GoodMoat Value
$131.68
36.9% overvaluedProfile
Valuation (TTM)
Market Cap$369.10B
P/E87.34
EV$424.43B
P/B—
Shares Out1.77B
P/Sales6.04
Revenue$61.16B
EV/EBITDA24.85
Abbvie Inc (ABBV) Valuation
ABBV Valuation Metrics
FCF$17.82B
FCF Growth Rate5.70%
EPS Growth (CAGR)5.70%
WACC10.00%
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →ABBV Valuation & Fair Value Analysis
Abbvie Inc (ABBV) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Abbvie Inc is $131.68. The current stock price is $208.84, suggesting the stock is 58.6% overvalued.
The price-to-earnings (P/E) ratio is 87.34. Price-to-sales ratio is 6.04. Enterprise value to EBITDA is 24.85. PEG ratio is -0.01.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Abbvie Inc's intrinsic value.